India Bioanalytical Testing Services Market Assessment, By Test Type, By Molecule, By Application, By End-user, By Region, Opportunities and Forecast, FY2018-FY2032F

India bioanalytical testing services market is projected to grow at a CAGR of 10.70% from FY2025 to FY2032, increasing from USD 90.35 million in FY2024 to USD 203.76 million by FY2032. Large patient populations have made India an ideal location for clinical trials, further fueling the growth of bioanalytical testing services in the country. In addition, an increasing number of biotechnology companies and rising demand for biologics and biosimilars will also promote market growth in the near future. Further, the cost-competitiveness of the service also acts as an impetus as it attracts outsourcing by most global pharmaceutical companies for their testing needs. Additionally, increased government initiatives and investments in the research activities of the life sciences sector are anticipated to fuel the adoption of bioanalytical testing services in the country.

India is increasingly focusing on drug discovery due to government initiatives and an ever-growing biotechnology sector. The Promotion of Research and Innovation in the Pharma MedTech Sector (PRIP) scheme promotes research and innovation in the Pharma MedTech sector along with AI and GenAI, thus promoting more efficient research and reduced costs for drug development. Companies are also investing in enhancing drug development in the country. For instance, in December 2023, Peptris Technologies Private Limited raised USD 1 million in pre-seed funding from Speciale Invest. This investment supports AI-driven drug discovery efforts focused on novel therapies for undruggable targets in oncology, inflammation, and rare diseases. Advances in AI and vast chemical libraries open new market opportunities. As drug discovery accelerates in the country, the need for bioanalytical testing services will surge to ensure new therapeutics are safe and effective enough to be put on the market, supporting market growth. Also, increased collaborations between academia and industry promote this trend and establish India as a key player in the global pharmaceutical landscape.

Expansion of Contract Research Organizations Impacts India Bioanalytical Testing Services Market

The rapid growth of India's pharmaceutical and biopharmaceutical industries significantly impacts the bioanalytical testing services market. Growing demand for drugs and biologics has pushed Contract Research Organizations (CROs) to expand their operations to keep pace with increasing demand for specialized testing, adopt cost-effective solutions, advance technology, and adhere to stringent regulatory standards. The collaborations between Indian CROs and pharmaceutical companies facilitate innovation and enhancement of service capabilities. These collaborations are imperative in providing holistic bioanalytical testing services, making India a significant global player. As such, growth in CROs directly enhances India's bioanalytical testing services market.

For instance, in November 2024, Bioneeds India Pvt Ltd. joined Contract Laboratory Network, strengthening its discovery, preclinical, and regulatory services across the domains. This acquisition would improve their market position and help accelerate the growth of bioanalytical testing services in India. Such a step would further follow the trend of overall growth in CRO, fostering collaborations, innovation, and opportunities within bioanalytical testing services, fueling further expansion and development in the industry.

Rising Demand for Biologics and Biosimilars Propels Market Growth

Increasing demand for biologics and biosimilars bolstered India's bioanalytical testing services market growth. Biologics are now more commonly used in chronic diseases like cancer and autoimmune diseases, for which biosimilars can be used more cost-effectively than biologics. Indian companies are also introducing new biologics and biosimilars to cater to the growing healthcare needs. This increased introduction will fuel the demand for bioanalytical testing services so that those products meet the set rigorous safety, efficacy, and regulatory standards. In addressing this demand, bioanalytical testing services have become a critical enabler for India's pharmaceutical industry in supporting its efforts to innovate and expand in biologics and biosimilars.

Pharmaceutical companies increased the number of new biosimilars in the market, which supported market growth. For instance, in January 2024, Glenmark Pharmaceuticals Ltd. launched a biosimilar of the anti-diabetic drug Liraglutide in India under the brand name 'Lirafit' after the Drug Controller General of India (DCGI) approval. All these launches increase the requirement for bioanalytical testing services in India to provide thorough testing and validation to ensure the efficacy and safety of newly launched biosimilars.

Pharmaceuticals and Biopharmaceuticals Companies Hold a Major Market Share

The pharmaceutical and biopharmaceutical companies hold the highest share in the Indian bioanalytical testing services market as they play the most crucial role in the development and manufacturing of drugs. These firms drive the market by investing in new biologics and biosimilars to cater to the domestic and international demand for advanced therapies. India's pharmaceutical giants are at the forefront of developing biosimilars for global markets. Their efforts also include pipeline development for monoclonal antibodies, vaccines, and other complex biologics that require stringent bioanalytical testing to comply with regulations. Indian firms' collaboration with international players also enhances the range of such testing services and provides easy access to state-of-the-art analytical technologies. For instance, in March 2024, Jubilant Biosys Ltd. expanded its presence in India and explored new therapeutic areas to provide drug discovery, development, and manufacturing services. It will keep pace with the ever-increasing demand for bioanalytical testing services, which is critical for maintaining Indian competitiveness in the global markets.

The growing emphasis on export-oriented biosimilar production also necessitates more extensive bioanalytical testing to meet the more stringent international regulatory requirements. Indian pharmaceutical companies are, therefore, partnering with specialized Contract Research Organizations (CROs) to outsource testing services, thereby enabling faster product development cycles with uncompromised quality. This collaboration between pharmaceutical companies and testing service providers strengthens India's position as a global hub for biologics and biosimilars and drives continuous innovation in methodologies for bioanalytical testing.

Future Market Scenario (FY2025-FY2032F)

The Indian bioanalytical testing market will experience significant growth in the coming years with development in AI, automation, and high throughput testing technologies. Pharmaceutical and biotechnology markets will grow because of policies such as "Make in India" and a focus on biosimilars. Thus, this will create an urgent demand for precise testing solutions. With growing clinical trials and research activities, there will be a growing demand for vaccines and biologics. Moreover, the increasing adoption of personalized medicine, stricter regulatory standards, and growing investments in health infrastructure also create opportunities for testing services.

For instance, the Indian pharmaceutical industry is increasing, providing high-value opportunities for bioanalytical testing services. With companies now focusing on innovative therapies, it is necessary to test with precision to confirm that the product is safe and effective. For instance, in August 2024, Amgen Inc., one of the biotech majors, established its technology and innovation center in Hyderabad, Telangana, called Amgen India. The facility will enhance the organization's digital capabilities globally and speed up Amgen's medicine pipeline.

Key Players Landscape and Outlook

Major players in the Indian bioanalytical testing services market are strengthening their footprints by enhancing R&D capabilities, forging strategic collaborations, and improving the testing infrastructure. They focus on diversified service portfolios catering to biosimilars, biologics, and personalized medicine. Moreover, companies are adopting advanced technologies and expanding their geographical reach to capture the growing demand from the pharmaceutical and biotechnology sectors, thereby providing sustained market growth in the following years.

In September 2023, Eurofins Scientific SE inaugurated its new bio-pharma services campus in Genome Valley in Hyderabad, which occupies one lakh sq ft of lab and office space. The facility strengthens its services in discovery chemistry, biology, toxicology, bio-analytical testing, and formulation development and is positioned to enhance its market share in India. This growth significantly increases market capacity regarding its service delivery, fosters innovation, and attracts pharmaceutical collaborations worldwide, thereby creating growth and development in the sector.